Sugi Predict

Sugi Predict / Compounds / Ceftriaxone

Ceftriaxone

Ceftriaxone

SCHEMBL3389557

CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(CSc3nc(=O)c(O)nn3C)CS[C@H]12)c1csc(N)n1.CO[C@@]1(NC(=O)C(C(=O)O)c2ccc(O)cc2)C(=O)N2C(C(=O)O)=C(CSc3nnnn3C)CO[C@@H]21

nearest known ligand 0.64

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

dacAdacBdacCftsImrcAmrcBmrdA

The experimentally established mechanism targets of Ceftriaxone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NR1I2 O75469 5/20 0.64
▸ PGR P06401 3/20 0.64
▸ PTGS1 P23219 1/20 0.62
▸ SLC22A6 Q4U2R8 4/20 0.54
▸ SLC22A8 Q8TCC7 4/20 0.54
▸ SLC22A11 Q9NSA0 4/20 0.54
▸ PPARG P37231 3/20 0.54
▸ DAO P14920 1/20 0.54
▸ SNCA P37840 1/20 0.54
▸ CYP2J2 P51589 1/20 0.54
▸ ABCC4 O15439 1/20 0.54
▸ MAPT P10636 4/20 0.53
▸ TDP1 Q9NUW8 3/20 0.53
▸ HSD17B10 Q99714 2/20 0.53
▸ CYP2D6 P10635 1/20 0.53
▸ KDM4E B2RXH2 1/20 0.53
▸ ALDH1A1 P00352 1/20 0.53
▸ POLB P06746 1/20 0.53
▸ APEX1 P27695 1/20 0.53
▸ RECQL P46063 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Moxalactam SCHEMBL28086495 0.96 NR1I2 (0.69) NR1I2PGRPTGS1SLC22A6SLC22A8
Moxalactam SCHEMBL6521966 0.93 NR1I2 (0.64) NR1I2PGRPTGS1SLC22A6SLC22A8
Moxalactam SCHEMBL13723425 0.90 PTGS1 (0.64) NR1I2PGRPTGS1SLC22A6SLC22A8
Ceftazidime SCHEMBL715368 0.86 NR1I2 (0.58) NR1I2PGRPTGS1SLC22A6SLC22A8
Moxalactam SCHEMBL22205083 0.84 NR1I2 (0.52) NR1I2PGRPTGS1SLC22A6SLC22A8
Ceftriaxone SCHEMBL23354 0.81 NR1I2 (0.80) NR1I2PGRSLC22A6SLC22A8SLC22A11
Ceftriaxone SCHEMBL30307091 0.81 NR1I2 (0.80) NR1I2PGRSLC22A6SLC22A8SLC22A11
Ceftriaxone SCHEMBL2006478 0.81 NR1I2 (0.80) NR1I2PGRSLC22A6SLC22A8SLC22A11
Ceftriaxone SCHEMBL8378294 0.81 NR1I2 (0.80) NR1I2PGRSLC22A6SLC22A8SLC22A11
Ceftriaxone SCHEMBL4897101 0.81 NR1I2 (0.80) NR1I2PGRSLC22A6SLC22A8SLC22A11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1418108-A Parenteral use of bacterial phage associated lysing enzymes for therapeutic treatment of bacterial infections NEW HORIZONS DIAGNOSTICS CORP (US) 2003-05-14 — — CN claimed
US-5409917-A Topical treatment of acne with cephalosporins Towsend, Marvin S. (US) 1995-04-25 — — US claimed
US-20240165246-A1 Treatment of Anthrax with Pegylated Capsule-Degrading Enzyme THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY 2024-05-23 — — US disclosed
US-11986534-B1 Treatment of anthrax with pegylated capsule-degrading enzyme THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) 2024-05-21 — — US disclosed
US-11786601-B2 Pegylated capsule-degrading enzyme for the treatment of anthrax THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) 2023-10-17 — — US disclosed
EP-2571984-A2 ANTIBACTERIAL PHAGE PEPTIDES AND METHODS OF USE THEREOF Lusomedicamenta, S.A. (PT) 2013-03-27 — — EP disclosed
US-20100226906-A1 Recombinant poly-glutamic acid depolymerases FRIEDLANDER ARTHUR M 2010-09-09 — — US disclosed
WO-2010041970-A2 ANTIBACTERIAL PHAGE PEPTIDES AND METHODS OF USE THEREOF LUSOMEDICAMENTA, S.A. (PT) 2010-04-15 — — WO disclosed
US-5409917-A Topical treatment of acne with cephalosporins Towsend, Marvin S. (US) 1995-04-25 — — US disclosed